Die Tuberkulosesituation in Deutschland 2000

Loddenkemper, R.; Brendel, Annelie; Sagebiel, Daniel; Forssbohm, M

doi:10.1055/s-2002-33851

Cited by 9 publications

(7 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although this study was performed in a regional area with a low incidence of tuberculosis [23], 2 patients were found to have positive tuberculosis test results by screening prior to treatment and were excluded from infliximab therapy. Since tuberculin tests may produce false-negative results in patients on immunosuppressive medication, a careful risk assessment and appropriate patient screening for tuberculosis (skin test with 0.1 ml s.c. and chest X-ray) should be routinely taken into consideration in the approach towards patients with Crohn’s disease prior to infliximab infusion.…”

Section: Discussionmentioning

confidence: 99%

Safety Aspects of Infliximab in Inflammatory Bowel Disease Patients

Seiderer¹,

Göke²,

Ochsenkühn³

2004

Digestion

View full text Add to dashboard Cite

Background: Infliximab, a chimeric anti-tumour necrosis factor monoclonal antibody with potent anti-inflammatory effects, represents an effective treatment option in patients with severe inflammatory bowel disease (IBD). Serious side-effects of such an immunomodulating therapy are speculated and therefore we reviewed our clinical experience in a retrospective safety study looking upon a single cohort of 100 IBD patients from a large German University Hospital. Methods: 100 patients with severe Crohn’s disease (n = 92), ulcerative colitis (n = 7) or indeterminate colitis (n = 1) treated with infliximab (5 mg/kg) from January 2000 to December 2003 were retrospectively analysed for acute and subacute adverse events by chart review. Results: Overall, infliximab therapy was generally well tolerated. No fatal complications, malignancies, autoimmune diseases, neurologic or cardiovascular complications were observed in the cohort during the study period. Overall, adverse events were observed in 10 patients: 2 patients showed an acute infusion reaction, 1 patient a serum sickness-like reaction, in 4 patients a bacterial or viral infection occurred, in 1 patient pancytopenia and 2 patients developed surgical complications. Only 6 patients with adverse events required admission to hospital. A case of tuberculosis after infliximab was not found. The lack of adverse side-effects was associated with young median age and infrequent comorbidities of the cohort. Conclusion: Regarding its strong immunomodulating capacity, infliximab appears to be an efficient and relatively safe therapeutic option for patients with severe IBD. However, the use of infliximab requires careful screening and close patient monitoring to identify patients at risk and the infrequent, but sometimes serious complications of infliximab.

show abstract

Section: Discussionmentioning

confidence: 99%

Safety Aspects of Infliximab in Inflammatory Bowel Disease Patients

Seiderer¹,

Göke²,

Ochsenkühn³

2004

Digestion

View full text Add to dashboard Cite

show abstract

“…Bezogen auf die gemeldeten Neuerkrankungen des Jahres 2001 handelte es sich bei 80% um eine Lungentuberkulose (n=5964), dieser Anteil ist über viele Jahre nahezu konstant geblieben [1,4]. Bei den extrapulmonalen Formen der Tuberkulose ist der extrathorakale Befall der Lymphknoten am häufigsten, darauf folgen Pleura,Urogenitaltrakt,Knochen/Gelenke und Meningen/ZNS.Bei 74 Erkrankungen (1,0%) handelte es sich um eine disseminierte Tuberkulose (Befall von 3 oder mehr Organen).…”

Section: Formen Der Tuberkuloseunclassified

Epidemiologie der Tuberkulose in Deutschland

Morr¹

2003

Der Internist

View full text Add to dashboard Cite

“…Dabei entfielen 84,3% auf die Tuberkulose der Atmungsorgane und 15,7% auf die Tuberkulose der anderen Organe (10 …”

Section: Late Tubercular Dissemination In Tubercular Spondylitisunclassified

“…Die höch-ste Inzidenz hatten mit 45,2 pro 100 000 Einwohner Männer, die 75 Jahre und älter waren (10). Unterschieden werden die Primärinfektion und die postprimäre Tuberkulose.…”

Section: Diskussionunclassified